Latest News

With major capacity investments behind it, Canadian National can now convert freight growth into pure profit without heavy new spending.

Established office brands are funding the transition to higher-margin tech accessories, a dual-engine strategy that could reshape profitability.

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.

Oklo has fallen hard from its all-time high of $194. Could today's price of $27 imply immense upside?

Data and AI bookings surged 29% as bill rates hit record highs.

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

New ETF HOID joins humanoid robotics funds KOID and IBOT, which differ in cost, holdings, and performance, as investors weigh long-term growth potential against fees and liquidity.

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Operating margins expanded 7.5 points year-over-year, showing how scale translates into earnings power for shareholders.

Investors had to know this day was coming sooner or later.

There's no better teacher than time, although mistakes are a close second.

Constrained supply and room-rate growth outpacing inflation create a rare window for margin expansion in lodging.

Management is fixing the weak link in its network while doubling down on high-margin logistics.

The economic impact is small so far, but it could grow.

Microsoft offered buyouts to about 60,000 employees amid record AI spending and strong earnings, raising questions about margins, cash flow, and whether AI will reshape its long-term staffing needs.

When you dig into the quarterly numbers, it looks like consumers are handling their debt well.

The head of the central bank just charted an undeniable path forward for interest rates.

There's a knock on the door. It's your local multiplex panning for gold with a silver screen.

Product innovation and disciplined acquisitions are positioning the company to triple free cash flow by 2030.

The bullish case for Nvidia keeps getting stronger.

Price discipline is protecting margins even as material costs climb, a test of Cavco's pricing power in a competitive market.

Pfizer's post-COVID comeback is still only in the early stages.

Positive automotive margins are within reach as R2 production scales, but software expansion may be the real long-term growth lever.